Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Short Interest Update

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) saw a large increase in short interest in June. As of June 30th, there was short interest totaling 7,748 shares, an increase of 94.0% from the June 15th total of 3,994 shares. Approximately 1.5% of the company’s shares are sold short. Based on an average trading volume of 35,104 shares, the days-to-cover ratio is presently 0.2 days.

Eloxx Pharmaceuticals Stock Performance

Shares of ELOX traded down $0.57 during mid-day trading on Thursday, hitting $12.02. 48,923 shares of the company’s stock were exchanged, compared to its average volume of 21,495. The company has a market capitalization of $8.29 million, a P/E ratio of -0.79 and a beta of -1,891.27. Eloxx Pharmaceuticals has a fifty-two week low of $11.41 and a fifty-two week high of $17.50. The company has a 50-day moving average of $17.45.

Eloxx Pharmaceuticals Company Profile

Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.